CleanCap® AG (3' OMe) Reagent: Next-Generation mRNA Capping Technology

CleanCap® enables a high-yield, streamlined manufacturing process that is cell-free and highly scalable for mRNA-based therapeutic and vaccine development. Unlike legacy methods, CleanCap offers a co-transcriptional, single-pot capping process that generates the optimal Cap1 structure. You can expect three times the transcriptional yield (4 mg/mL) and a much-improved capping efficiency (>95%) over traditional methods.

The mRNA cap structure is an important point of consideration for the immunogenicity of your mRNA-based product. Whereas legacy cap analogs produce a Cap0 structure and are recognized by the immune system as foreign, the CleanCap generated Cap1 product can evade innate immune detection. With CleanCap, you get the beneficial Cap1 structure and, in turn, better in vivo performance.

CleanCap is available as a standalone reagent or as a part of TriLink’s custom mRNA manufacturing services. TriLink offers multiple quality grades of CleanCap reagent and custom services. Contact TriLink to learn more about the full range of mRNA manufacturing solutions available.